The Europe Alzheimer’s disease therapeutics & diagnostics market is estimated to propel with a 6.80% CAGR between the forecast years 2022 and 2030, generating $3602.33 million in revenue by 2030.
EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET FORECAST 2022-2030
Europe Alzheimer’s Disease Market by Therapeutics & Diagnostics (Therapeutics (Drugs, Disease Stage, Generic & Branded) Diagnostics (Lumbar Puncture Test, Positron Emission Tomography, Electroencephalography, Magnetic Resonance Imaging, Computed Tomography, Blood Test, Other Diagnostics)) by Geography
The Europe Alzheimer’s disease therapeutics & diagnostics market is estimated to propel with a 6.80% CAGR between the forecast years 2022 and 2030, generating $3602.33 million in revenue by 2030.
The rising mortality rate mainly drives the European market due to Alzheimer’s disease (AD). Also, government efforts such as conferences and meetings to promote the awareness of Alzheimer’s disease significantly. In addition, the rising geriatric population and cases of neurodegenerative diseases are important factors supplementing the market growth. Moreover, increasing research & development investment and several new drugs in the pipeline are anticipated to further fuel the market growth.
To know more about this report, request a free sample copy
The Europe Alzheimer’s disease therapeutics & diagnostics market growth evaluation entails the analysis of Italy, Poland, France, United Kingdom, Belgium, Germany, and Rest of Europe. In the United Kingdom, as per the National Clinical Trials Registry (NCT), about 25 clinical trials are active and developing the cure for Alzheimer’s disease. Moreover, with the COVID-19 outbreak, the number of clinical trials is anticipated to increase slowly, primarily due to the shortage of resources & patient availability. Authorities are investing heavily in building appropriate infrastructure to manage the rising prevalence of AD while anticipating the launch of new therapeutics.
In Germany, the elderly population is expected to witness growth in the future. They are prone to neurological disorders, such as Alzheimer’s disease or dementia. Thus, the growing geriatric population and the rising prevalence of dementia in Germany are expected to drive the growth of the Alzheimer’s disease diagnostics and therapeutics market over the forecast period. Further, it has also been observed that some regions developed regional dementia strategies and are working toward implementing them. These plans cover actions to improve awareness, early diagnosis, and enabling support in the home.
The market segmentation analysis of the Europe Alzheimer’s disease therapeutics & diagnostics includes therapeutics & diagnostics.
The therapeutics state can be divided into disease stages, covering the early/middle stage: mild to moderate AD, late-stage: severe AD, and prodromal stage. According to disease severity, the general course of Alzheimer’s disease is categorized into seven stages. However, as it is difficult to distinguish the steps of drug development, a three-stage categorization is preferred: severe, moderate, and mild. These three stages address symptomatic cases of the disease.
Moreover, the molecular pathology of AD can precede the onset of symptoms by more than a decade. People in the high-risk group may exhibit AD pathology without any symptoms evident. This population is addressed under the fourth disease stage called prodromal AD, which is interchangeably used with MCI.
Some of the key players in the Europe Alzheimer’s disease therapeutics & diagnostics market include GE Healthcare, Novartis AG, F. Hoffmann-La Roche, Pfizer Inc, etc.
Pfizer Inc is a biopharmaceutical company having its headquarters in New York. The company discovers, develops, manufactures, and markets medicines, vaccines, and consumer healthcare products. The company offers products to treat cardiovascular, respiratory, and metabolic conditions, diseases, inflammation, cancer, infection, neurological problems, pain, tissue repair, ophthalmic diseases, orphan diseases, gastrointestinal diseases, genitourinary infections, and women’s health issues. The company operates across the Americas, the Asia-Pacific, Europe, and the Middle East & Africa. Pfizer has its headquarters in New York, United States.
Aricept, one of Pfizer’s popular products, is the first and only FDA-approved prescription medication to treat all stages of AD, including severe, mild, and moderate dementia caused by Alzheimer’s. The medicine does not cure AD but may provide symptomatic benefits for some patients. However, Aricept works differently for every person.
Report Synopsis
| Report Scope | Details |
| Market Forecast Years | 2022-2030 |
| Base Year | 2021 |
| Market Historical Years | 2018-2021 |
| Forecast Units | Revenue ($ Million) |
| Segments Analyzed | Therapeutics & Diagnostics |
| Countries Analyzed | United Kingdom, Germany, France, Italy, Belgium, Poland, and Rest of Europe |
| Companies Analyzed | Allergan PLC, Amarantus, BioScience Holdings Inc, Baxter International Inc, Biogen Inc, Cognoptix Inc, Eisai Co Ltd, Eli Lilly & Company, F Hoffmann-La Roche, GE Healthcare, Johnson & Johnson, Lupin Limited, Merck & Co Inc, Novartis AG, Pfizer Inc, Siemens Healthineers AG, Sun Pharmaceuticals Industries Ltd, Teva Pharmaceutical Industries Limited, Zydus Cadila |
To request a free sample copy of this report, please complete the form below:
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.
- RESEARCH SCOPE & METHODOLOGY
- STUDY OBJECTIVES
- SCOPE OF STUDY
- METHODOLOGY
- ASSUMPTIONS & LIMITATIONS
- EXECUTIVE SUMMARY
- MARKET SIZE & ESTIMATES
- MARKET OVERVIEW
- MARKET DYNAMICS
- PARENT MARKET ANALYSIS
- KEY DRIVERS
- GROWING GERIATRIC POPULATION
- RISING PERVASIVENESS OF ALZHEIMER’S DISEASE
- EMERGING NOVEL DIAGNOSTIC TECHNOLOGIES
- INCREASING PIPELINE DRUGS
- KEY RESTRAINTS
- FAILURE OF THE LATE-STAGE DRUGS
- STRINGENT GOVERNMENT REGULATIONS
- LACK OF THE AVAILABILITY OF SURROGATE MARKERS
- KEY ANALYTICS
- TIMELINE OF ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
- PHASES AND STERNNESS OF ALZHEIMER’S DISEASE
- IMPACT OF COVID-19 ON ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
- KEY MARKET TRENDS
- PORTER’S FIVE FORCES ANALYSIS
- BUYERS POWER
- SUPPLIERS POWER
- SUBSTITUTION
- NEW ENTRANTS
- INDUSTRY RIVALRY
- KEY BUYING CRITERIA
- SUPPLY CHAIN ANALYSIS
- OPPORTUNITY MATRIX
- VENDOR LANDSCAPE
- MARKET BY THERAPEUTICS & DIAGNOSTICS
- THERAPEUTICS
- DRUGS
- MARKETED DRUGS
- PIPELINE DRUGS
- DISEASE STAGE
- LATE-STAGE: SEVERE AD
- EARLY/MIDDLE STAGE: MILD TO MODERATE AD
- PRODROMAL STAGE
- GENERIC & BRANDED
- BRANDED
- GENERIC
- DRUGS
- DIAGNOSTICS
- LUMBAR PUNCTURE TEST
- POSITRON EMISSION TOMOGRAPHY
- ELECTROENCEPHALOGRAPHY
- MAGNETIC RESONANCE IMAGING
- COMPUTED TOMOGRAPHY
- BLOOD TEST
- OTHER DIAGNOSTICS
- THERAPEUTICS
- GEOGRAPHICAL ANALYSIS
- EUROPE
- MARKET SIZE & ESTIMATES
- KEY GROWTH ENABLERS
- KEY CHALLENGES
- KEY PLAYERS
- COUNTRY ANALYSIS
- UNITED KINGDOM
- GERMANY
- FRANCE
- ITALY
- BELGIUM
- POLAND
- REST OF EUROPE
- EUROPE
- COMPETITIVE LANDSCAPE
- KEY STRATEGIC DEVELOPMENTS
- MERGERS & ACQUISITIONS
- PRODUCT LAUNCHES & DEVELOPMENTS
- PARTNERSHIPS & AGREEMENTS
- BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES
- COMPANY PROFILES
- ALLERGAN PLC (ACQUIRED BY ABBVIE)
- AMARANTUS BIOSCIENCE HOLDINGS INC
- BAXTER INTERNATIONAL INC
- BIOGEN INC
- COGNOPTIX INC
- EISAI CO LTD
- ELI LILLY & COMPANY
- F HOFFMANN-LA ROCHE
- GE HEALTHCARE
- JOHNSON & JOHNSON
- LUPIN LIMITED
- MERCK & CO INC
- NOVARTIS AG
- PFIZER INC
- SIEMENS HEALTHINEERS AG
- SUN PHARMACEUTICALS INDUSTRIES LTD
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- ZYDUS CADILA
- KEY STRATEGIC DEVELOPMENTS
LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS
TABLE 2: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 3: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 4: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 5: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 6: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 7: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 8: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 9: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 10: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 11: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 12: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 13: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 14: LEADING PLAYERS OPERATING IN EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
TABLE 15: LIST OF MERGERS & ACQUISITIONS
TABLE 16: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 17: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 18: LIST OF BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES
LIST OF FIGURES
FIGURE 1: PIPELINE DRUGS RELATED TO ALZHEIMER’S DISEASE
FIGURE 2: KEY MARKET TRENDS
FIGURE 3: PORTER’S FIVE FORCES ANALYSIS
FIGURE 4: KEY BUYING CRITERIA
FIGURE 5: SUPPLY CHAIN ANALYSIS
FIGURE 6: OPPORTUNITY MATRIX
FIGURE 7: VENDOR LANDSCAPE
FIGURE 8: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY THERAPEUTICS & DIAGNOSTICS, IN 2021
FIGURE 9: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2030 (IN $ MILLION)
FIGURE 10: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DRUGS, IN 2021
FIGURE 11: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2030 (IN $ MILLION)
FIGURE 12: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2030 (IN $ MILLION)
FIGURE 13: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DISEASE STAGE, IN 2021
FIGURE 14: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE-STAGE: SEVERE AD, 2022-2030 (IN $ MILLION)
FIGURE 15: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2022-2030 (IN $ MILLION)
FIGURE 16: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2030 (IN $ MILLION)
FIGURE 17: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY GENERIC & BRANDED, IN 2021
FIGURE 18: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2030 (IN $ MILLION)
FIGURE 19: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2030 (IN $ MILLION)
FIGURE 20: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2030 (IN $ MILLION)
FIGURE 21: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY DIAGNOSTICS, IN 2021
FIGURE 22: EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2022-2030 (IN $ MILLION)
FIGURE 23: EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2022-2030 (IN $ MILLION)
FIGURE 24: EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2022-2030 (IN $ MILLION)
FIGURE 25: EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2022-2030 (IN $ MILLION)
FIGURE 26: EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2022-2030 (IN $ MILLION)
FIGURE 27: EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2030 (IN $ MILLION)
FIGURE 28: EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2030 (IN $ MILLION)
FIGURE 29: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
FIGURE 30: UNITED KINGDOM ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 31: GERMANY ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 32: FRANCE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 33: ITALY ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 34: BELGIUM ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 35: POLAND ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 36: REST OF EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
- GEOGRAPHICAL ANALYSIS
- EUROPE
- MARKET SIZE & ESTIMATES
- KEY GROWTH ENABLERS
- KEY CHALLENGES
- KEY PLAYERS
- COUNTRY ANALYSIS
- UNITED KINGDOM
- GERMANY
- FRANCE
- ITALY
- BELGIUM
- POLAND
- REST OF EUROPE
- EUROPE
- MARKET BY THERAPEUTICS & DIAGNOSTICS
- THERAPEUTICS
- DRUGS
- MARKETED DRUGS
- PIPELINE DRUGS
- DISEASE STAGE
- LATE-STAGE: SEVERE AD
- EARLY/MIDDLE STAGE: MILD TO MODERATE AD
- PRODROMAL STAGE
- GENERIC & BRANDED
- BRANDED
- GENERIC
- DRUGS
- DIAGNOSTICS
- LUMBAR PUNCTURE TEST
- POSITRON EMISSION TOMOGRAPHY
- ELECTROENCEPHALOGRAPHY
- MAGNETIC RESONANCE IMAGING
- COMPUTED TOMOGRAPHY
- BLOOD TEST
- OTHER DIAGNOSTICS
- THERAPEUTICS
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.